<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Phase II Lymphoma Study &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/phase-ii-lymphoma-study/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 09:06:19 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Phase II Lymphoma Study &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>New Trial Tests Venetoclax, Ibrutinib Combo Against Mantle Cell Lymphoma</title>
		<link>https://bioengineer.org/new-trial-tests-venetoclax-ibrutinib-combo-against-mantle-cell-lymphoma/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 25 Aug 2025 04:19:14 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Elderly Oncology Clinical Trials]]></category>
		<category><![CDATA[Mantle Cell Lymphoma Treatment]]></category>
		<category><![CDATA[Phase II Lymphoma Study]]></category>
		<category><![CDATA[Targeted Therapy and Chemo-Immunotherapy]]></category>
		<category><![CDATA[Venetoclax-Ibrutinib Combination Therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/new-trial-tests-venetoclax-ibrutinib-combo-against-mantle-cell-lymphoma/</guid>

					<description><![CDATA[In a groundbreaking advancement for the treatment of mantle cell lymphoma (MCL), an international phase II clinical trial known as the MCL Elderly III trial is investigating innovative therapeutic combinations tailored specifically for elderly patients who are ineligible for intensive chemotherapy regimens. This trial seeks to redefine the treatment landscape of this aggressive B-cell non-Hodgkin [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">257500</post-id>	</item>
	</channel>
</rss>
